S-1: DiamiR Biosciences Corp. Files for IPO, Aims to Advance Blood-Based Diagnostics for Neurodegenerative Diseases

DiamiR Biosciences Corp. files an S-1 registration statement for an initial public offering to fund the development and commercialization of blood-based diagnostic tests for neurodegenerative diseases.

Summary

• DiamiR Biosciences Corp., a molecular diagnostics company, has filed an S-1 registration statement for an IPO.
• The company aims to develop and commercialize blood-based tests for early detection and monitoring of neurodegenerative diseases like Alzheimer's and Parkinson's.
• The IPO proceeds will be used for working capital, development and launch of CogniMIR (a test for early detection of Alzheimer's), marketing and sales, and establishing CLIA lab capabilities.
• The company's technology is based on analyzing organ-enriched microRNAs (miRNAs) in plasma.
• DiamiR has a limited operating history and has incurred net losses since inception, with an accumulated deficit of $4,780,260 as of February 29, 2024.
• The company expects to continue incurring net losses and negative cash flows for the foreseeable future.
• The offering includes the resale of shares by selling shareholders and shares underlying underwriters' warrants.
• The company has applied to list its common stock on the Nasdaq Capital Market under the symbol DIMR.
• Kira Sheinerman and Samuil Umansky, the co-founders, currently own and control a combined 84.9% of the company's outstanding common stock.
• The company faces competition from other major molecular diagnostics companies and is subject to regulations by the FDA and CLIA.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company is pursuing an IPO to advance its diagnostic technology, it also acknowledges its limited operating history, net losses, and dependence on future funding. The document also highlights the competitive landscape and regulatory challenges.

Positives

• The company's technology is based on analyzing organ-enriched microRNAs (miRNAs) in plasma, which can cross the blood-brain barrier and appear in the bloodstream.
• The company has established collaborative relationships with leading clinical research organizations in the area of neurodegenerative diseases.
• The company has 51 issued patents in the US and worldwide related to its miRNA biomarker technology.
• The company has received SBIR grants totaling approximately $9.0 million.
• The company has completed analytical validation of its 24-microRNA panel for risk assessment of Alzheimer's disease, CogniMIR.

Negatives

• The company has a limited operating history and has incurred net losses since inception, with an accumulated deficit of $4,780,260 as of February 29, 2024.
• The company expects to continue incurring net losses and negative cash flows for the foreseeable future.
• The company is dependent on key personnel, and the loss of their services could have an adverse effect on the business.
• The company faces significant competition from other major molecular diagnostics companies.
• The company is subject to regulations by the FDA and CLIA, including the FDA's recent final rule on LDTs, which could increase costs and delay product launches.

Risks

• The company's auditors have indicated substantial doubt about its ability to continue as a going concern.
• The company has limited capital resources and operations and may require substantial additional capital in the near future.
• The company faces significant, evolving competition which, if not properly addressed, could adversely affect its business.
• The company's operations are dependent upon its key personnel, and the loss of such personnel could negatively impact the business.
• The company will incur increased costs as a result of being a public company.
• The company has identified material weaknesses in its internal control over financial reporting.
• Insiders have substantial control over the company, and they could delay or prevent a change in corporate control.
• The company may be deemed a controlled company within the meaning of the rules of Nasdaq.
• The company may be unable to commercialize CogniMIR or any other products it may develop on a timely basis, or at all.
• The company's research and development efforts will be hindered if it is not able to acquire or contract with third parties for access to additional plasma samples.
• The company relies on a sole supplier for some of the materials used in its tests and services, and it may not be able to find replacements or transition to alternative suppliers in a timely manner.
• If the company cannot enter into and maintain new clinical collaborations, its efforts to commercialize CogniMIR and its development of other products could be delayed.
• If the company's clinical tests do not perform as expected in its validation studies, it may not be able to achieve widespread market adoption among physicians.
• The company may be subject to legal claims arising from any defects or errors in its clinical services tests.
• The company's ability to commercialize the diagnostic products that it develops is dependent on its relationships with laboratory services providers and support of its products.
• The company may use third party collaborators to help it develop, validate, or commercialize any new products, and its ability to commercialize such products could be impaired or delayed if these collaborations are unsuccessful.
• If the company cannot enter into new clinical study collaborations, its product development and subsequent commercialization could be delayed.
• If the company is unable to use or maintain its trademarks and trade names or build brand recognition in its markets of interest, its business may be adversely affected.
• The company may be unable to develop new products and services or acquire products and services on favorable terms.
• If the company's laboratory becomes inoperable for any reason, it will be unable to perform its testing and its business will be harmed.
• If the company's landlord does not renew its lease, its clinical and testing operations will be halted until it locates and sets up a new laboratory.
• If the company's information technology or communications systems fail or it experiences a significant interruption in their operation, its reputation, business and results of operations could be materially and adversely affected.
• The company may now or in the future be subject to laws and regulations relating to laboratory testing, which could materially adversely impact its ability to offer its products or services.
• Maintaining adequate sales of its product, if any of its product candidates are approved, may depend on the availability of adequate reimbursement to its customers from third-party payers.
• If any of the company's product candidates are approved, it may be adversely affected by healthcare policy changes, including additional healthcare reform and changes in managed healthcare.
• The regulatory processes applicable to the company's products and operations are expensive, time-consuming, and uncertain and may prevent it from obtaining required authorizations for the commercialization of its products.
• Until the company secures FDA premarket review for CogniMIR it may not be able to launch it as an LDT.
• The company intends to market some of its tests as LDTs, and future changes in FDA enforcement discretion for LDTs could subject its operations to much more significant regulatory requirements.
• The company and its suppliers, contract manufacturers and customers are subject to various governmental laws and regulations, and it may incur significant expenses to comply with, and experience delays in its product commercialization as a result of, these laws and regulations.
• If the company fails to comply with federal, state and foreign laboratory licensing requirements, it could lose the ability to perform its tests or experience disruptions to its business.
• The company may be unable to protect or obtain proprietary rights.
• Intellectual Property infringement claims by other companies could result in costly disputes and could limit the company's ability to sell its products.
• If product liability lawsuits are successfully brought against the company, it may incur substantial liabilities and may have to limit or cease sales of its products.
• The market price of the company's securities may fluctuate significantly in response to a variety of factors, some of which are beyond the company's control.
• There is no market for the securities offered hereby.
• The Offering price and other terms of this Offering have been arbitrarily determined and may not be indicative of future market prices.
• Our management will have broad discretion in how we use the net proceeds of this offering and might not use them effectively.
• When this registration statement becomes effective, there will be a significant number of shares of Common Stock eligible for sale, which could depress the market price of such stock.
• Future sales of our securities may affect the market price of the Common Stock and result in material dilution.
• Any market that develops in shares of our common stock will be subject to the penny stock regulations and restrictions, which could impair liquidity and make trading difficult.
• We have established preferred stock which can be designated by our Board of Directors without shareholder approval.
• Anti-takeover provisions in our Certificate of Incorporation and our Bylaws, as well as provisions of Delaware law, might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the trading price of our common stock.

Future Outlook

The company expects to continue incurring net losses and negative cash flows for the foreseeable future as it conducts clinical studies and develops its infrastructure.

Management Comments

• Statements made by several experts within the field, in the report titled Technology Niche Analysis for CogniMIR titled In Vitro Test for Early Detection and Monitoring of Alzheimers Disease (Project #: NIH1052TN), in the publication Foresight Science & Technology, further support commercial and clinical potential of our approach.
• According to a comprehensive report published by the Alzheimers Association (2019 Alzheimers Disease Facts and Figures): Finding a simple and inexpensive test, such as a blood test, to diagnose Alzheimers would be ideal for patients, physicians and scientists.
• A more recent report from the Association (2023 Alzheimers Disease Facts and Figures) stated: The relatively recent discovery that Alzheimers disease begins 20 years or more before the onset of symptoms suggests that there is a substantial window of time in which we may be able to intervene in the progression of the disease.

Industry Context

The company operates in the competitive molecular diagnostics market, specifically targeting the growing need for early detection and monitoring of neurodegenerative diseases like Alzheimer's. The company's blood-based miRNA technology offers a less invasive and potentially more cost-effective alternative to existing methods like neuroimaging and cerebrospinal fluid analysis.

Comparison to Industry Standards

• The company is developing blood-based tests for Alzheimer's disease, which is an area of active research and development.
• Several companies, including Quanterix, C2N Diagnostics, and ALZPath, are developing biomarker tests for early detection of AD.
• Quanterix (via its subsidiary Lucent Diagnostics), C2N Diagnostics, and Quest Labs have launched commercial LDTs for AD based on select protein biomarkers (A b 42/40, p-Tau217, and p-Tau181).
• The company's miRNA-based approach is distinct from these protein-based tests, potentially offering a complementary diagnostic tool.
• The company's tests are currently not commercially available, while other companies have already launched LDTs for AD.
• The company's success will depend on its ability to demonstrate the clinical validity and utility of its tests and secure reimbursement from payers.

Related Party Transactions

• On March 15, 2023, the company issued convertible promissory notes to Samuil R. Umansky and Kira Sheinerman in the approximate amount of $86,826 and $405,189, respectively.
• On October 10, 2023, the company amended and restated Kira Sheinerman's note, pursuant to which she loaned the company an additional $100,000 and in March 2024 Dr. Sheinerman loaned the company an additional $100,000, increasing the value of her note to $623,242, including accrued interest.
• On March 30, 2023, the company entered into an insider stock purchase agreement with Kira Sheinerman, pursuant to which it issued her 14,265 shares of common stock for $100,000.

Stakeholder Impact

• Shareholders: Potential dilution from the IPO and future equity offerings.
• Employees: Potential for job creation and career advancement as the company grows.
• Customers: Access to innovative blood-based diagnostic tests for early detection and monitoring of neurodegenerative diseases.
• Suppliers: Potential for increased business opportunities as the company expands its operations.
• Creditors: Increased financial stability and ability to repay debts if the IPO is successful.

Next Steps

• The company intends to use proceeds from the Offering for working capital, support development and launch of our first test, CogniMIR, and other LDTs under CLIA guidelines, marketing, and sales, and establish or acquire DiamiRs CLIA lab capabilities and other general corporate purposes.
• The company plans on initiating a clinical validation study to demonstrate the diagnostic performance of our assay using large cohorts of well-characterized clinical samples to satisfy CLIA and CAP requirements.
• The company will work closely with licensing and regulatory agencies to ensure that clinical validity and utility of the tests satisfy all necessary requirements and quality control standards.
• The company will implement a robust commercial strategy aimed at securing coverage and contracting with Medicare and private payors.

Key Dates

Keywords

molecular diagnostics, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, microRNA, blood-based tests, CogniMIR, IPO, biomarkers, diagnostics